Benefit profile of recombinant human soluble thrombomodulin in sepsis-induced DIC

K Yamakawa, H Ogura,S Fujimi, M Morikawa, Y Ogawa, Y Umemura,Y Inoue, H Tanaka,T Hamasaki,T Shimazu

Critical Care（2014）

引用 0|浏览4

暂无评分

摘要

Recombinant human soluble thrombomodulin (rhTM) demonstrated promising evidence suggestive of efficacy in a phase IIb, randomized, controlled trial [1] and is currently under evaluation in a phase III trial. However, the benefit profiles of rhTM have not been elucidated. The purpose of this study was to explore whether patients with a high disease severity (according to Acute Physiology and Chronic Health Evaluation (APACHE) II and Sequential Organ Failure Assessment (SOFA) scores) might have a treatment benefit from rhTM administration.

查看译文

关键词

Retrospective Cohort Study,Sequential Organ Failure Assessment,Referral Hospital,Sequential Organ Failure Assessment Score,Adjust Hazard Ratio

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要